Life Sciences Company Developing Device to Prevent Blindness Caused by Diabetes

March 13, 2013

Early-stage medical device company Vasoptic Medical Inc. is conducting tests on a device to detect and prevent a progressively worsening eye condition that leads to blindness.

 

The tests, being held at the Johns Hopkins Wilmer Eye Institute, are required for federal Food and Drug Administration approval. When done in 2014, the Columbia company will seek FDA clearance to market and sell the device.

 

CEO and general counsel M. Jason Brooke estimates it will cost $7.5 million to bring the device to market. The federal National Institute of Health last year awarded the team a $225,000 development grant. The company next month will apply for a $1 million to $1.5 million NIH Small Business Innovation grant, which is intended to help speed commercialization of promising technology.

 

For full story click here.

Share on Facebook
Share on Twitter
Please reload

Recent News

Vasoptic Medical impresses at ARVO 2017

May 15, 2017

Vasoptic Medical's $1.5 million cash infusion pushes it toward FDA approval

April 25, 2017

Early Detection: New Device Measures Risk of Blindness from Diabetes

October 7, 2016

1/10
Please reload

© 2020 Vasoptic Medical Inc.

1215 E. Fort Ave Suite 304
Baltimore, MD 21230